Tech Company Financing Transactions
Meissa Vaccines Funding Round
On 8/5/2017, Meissa Vaccines announced investment from FundRx.
Transaction Overview
Company Name
Announced On
8/5/2017
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
FundRx (Gurdane Bhutani)
Proceeds Purpose
This investment is intended to help finance the Company to an investigational new drug (IND) filing for its lead asset, a live attenuated RSV vaccine candidate for infants.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1100 Island Dr. 202
Redwood City, CA 94065
USA
Redwood City, CA 94065
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Meissa Vaccines is a start-up pharmaceutical development company focused on the in-licensing and advancement of vaccines for respiratory syncytial virus (RSV, the largest unmet respiratory medical need in pediatrics) and rhinovirus (leading cause of infectious disease worldwide).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Marty Moore
Chief Medical Officer
Karen Slobod
Chief Scientific Officer
Roderick Tang
VP - Operations
Janelle Muranaka
VP - Regulatory Affairs
Fiona Cameron
Browse more venture capital transactions:
Prev: 8/5/2017: Universal Standard venture capital transaction
Next: 8/5/2017: StreetShares venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs